CA Patent

CA2835272A1 — Pharmaceutical antiretroviral composition

Assigned to Cipla Ltd · Expires 2012-12-06 · 13y expired

What this patent protects

The present invention relates to a pharmaceutical antiretro viral, composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition a…

USPTO Abstract

The present invention relates to a pharmaceutical antiretro viral, composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.

Drugs covered by this patent

Patent Metadata

Patent number
CA2835272A1
Jurisdiction
CA
Classification
—
Expires
2012-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Cipla Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.